Royal Bank of Canada
TTNP

Royal Bank of Canada’s Titan Pharmaceuticals TTNP Stock Holding History

Royal Bank of Canada’s Portfolio TTNP Stock Details TTNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1
Closed – – 7695
2021
Q1 		$0 Buy
+1
New +$66 ﹤0.01% 7708
2020
Q4 		– Hold
0
– – – 7295
2020
Q3 		– Hold
0
– – – 6935
2020
Q2 		– Hold
0
– – – 6912
2020
Q1 		– Hold
0
– – – 7026
2019
Q4 		– Hold
0
– – – 7123
2019
Q3 		– Hold
0
– – – 7127
2019
Q2 		– Hold
0
– – – 7187
2019
Q1 		– Hold
0
– – – 7109
2018
Q4 		– Hold
0
– – – 7117
2018
Q1 		– Hold
0
– – – 6793
2017
Q4 		– Hold
0
– – – 6898
2017
Q3 		– Hold
0
– – – 6986
2017
Q2 		– Hold
0
– -$3K – 6764
2017
Q1 		– Hold
0
– – – 6365
2016
Q4 		– Hold
0
– – – 6304
2016
Q2 		– Sell
-2
Closed -$26K – 6527
2016
Q1 		$26K Hold
2
– – ﹤0.01% 5392
2015
Q4 		$24K Buy
+2
New +$32.6K ﹤0.01% 5646

Other funds holding TTNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
ASN
Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Royal Bank of Canada's TTNP Position: Q2 2021 in Review

Royal Bank of Canada sold out of Titan Pharmaceuticals (TTNP) in Q2 2021, closing a stake of 1 share.

Royal Bank of Canada first reported a position in TTNP in Q4 2015 and held it in 3 quarters. The position peaked at $26K in Q1 2016. 16 funds tracked by Wall St. Rank hold TTNP as of Q2 2021.

  • Royal Bank of Canada reported no remaining Titan Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Royal Bank of Canada sold 1 Titan Pharmaceuticals share in Q2 2021.
  • Royal Bank of Canada first reported a position in Titan Pharmaceuticals in Q4 2015 and held it in 3 quarters.
  • Royal Bank of Canada's Titan Pharmaceuticals position peaked at $26K in Q1 2016.
  • 16 funds tracked by Wall St. Rank held Titan Pharmaceuticals as of Q2 2021.

Based on Royal Bank of Canada's 13F filing for Q2 2021, filed 16 Aug 2021.